Tags : Immuno- Oncology


GenScript Signs an Agreement with Selecxine to Develop Therapies for

Shots: GenScript will be responsible for all pre-clinical pharmacy research and IND filling in Selecxine’s project which is based on cytokine-antibody complexes The company provided development solutions in different hosts tailored to customers and provided the preparation and purification solutions for the final complex,; further the project will test and enhance the process development capability […]Read More


Merck KGaA Signs a License Agreement with Y-Trap to Develop

Shots: Y-Trap to receive up front, pre/clinical development, regulatory & commercial milestones with royalties on sales. Merck KGaA & Y-Trap will explore pharmacology of Y-Trap multifunctional proteins while Merck will be responsible for development, manufacturing and commercialization activities The collaboration involves Y-Trap’s platform of multifunctional antibody-ligand traps for immuno-oncology and Merck KGaA’s expertise in the […]Read More


Boehringer Ingelheim Collaborates with PureTech to Develop Immuno-Oncology Candidates for

Shots: PureTech to receive $26M as an upfront including research funding & preclinical milestone, $200M as development and commercial milestones and royalties on sales. Boehringer to develop immune-oncology candidates after it enters to development stage by utilizing PureTech’s lymphatic targeting technology The focus of the collaboration is to develop immuno-oncology candidates for gastrointestinal (GI) cancers […]Read More

Biotech Pharma

Takeda Collaborates with LegoChem Biosciences (LCB) to Develop Antibody-Drug Conjugates

Shots: LCB to receive $7.25M upfront, $404M as regulatory & commercial milestones and royalties on sales of ADCs product. Takeda licenses rights for LCB’s ConjuAll technology including linker and conjugation platform to develop & commercialize targetted immune-oncology therapies for three targets The focus of the collaboration is to utilize LCB’s ADC technology including linker and […]Read More


AstraZeneca and AVEO Oncology Enter into an Immuno-Oncology Clinical Collaboration

Shots: AstraZeneca and AVEO collaborates to evaluate safety and efficacy of AstraZeneca’s Imfinzi (durvalumab) + AVEO’s Fotivda (tivozanib) in P-I/II for 1L HCC or liver cancer AVEO plans to initiate the onset of P-I trial for the combination therapy in 2019, with equal cost sharing Imfinzi (durvalumab) is mAb binds with PD-L1, further blocking its interaction with PD-1 and […]Read More


I-Mab Biopharma Expands Collaboration with Wuxi Biologics for three more

Shots: I-Mab plans to license WuxiBody a proprietary platform from Wuxi for the development of three bispecific antibodies with focus on immuno-oncology and auto-immune This colloboration is the expansion of 2017 agreement between the companies which was intended for development and manufacturing of I-Mab pipeline products WuXiBody bispecifics have achieved 16g/L in cell culture titer, […]Read More


BioLineRx Annouces Expansion of 2016 Collaboration with Merck&Co. in Immuno-Oncology

Shots: Under the expansion collaboration, new arm of assessment is added assessing BL-8040, Keytruda and chemo in 2L patient in COMBAT/KEYNOTE-202 study  Results of Ph2a COMBAT study is expected in H2’18 as planned This study is assessing combination of BL-8040 & Keytruda in metastatic 1L+ patients Click here to read full press release/ article | Ref: Biolinerx […]Read More